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Purpose. The purpose of this study was to evaluate the feasibility of delivering vapreotide, a
somatostatin analogue, by transdermal iontophoresis.
Methods. In vitro experiments were conducted using dermatomed porcine ear skin and heat-separated
epidermis. In addition to quantifying vapreotide transport into and across the skin, the effect of peptide
delivery on skin permselectivity was also measured. The influence of (1) current density, (2) pre- and
post-treatment of the skin, (3) competitive ions, and (4) inclusion of albumin in the receptor on vapreotide
delivery were investigated.
Results. Epidermis proved to be a better model than dermatomed skin for vapreotide transport studies.
Despite the susceptibility of vapreotide to enzymatic degradation, a flux of 1.7 mg/cm2 per hour was
achieved after 7 h of constant current iontophoresis (0.15 mA/cm2). Post-iontophoretic extraction
revealed that, depending on the experimental conditions, 80Y300 mg of peptide were bound to the skin.
Vapreotide was found to interact with the skin and displayed a current-dependent inhibition of
electroosmosis. However, neither the pre-treatment strategies to saturate the putative binding sites nor
the post-treatment protocols to displace the bound peptide were effective.
Conclusion. Based on the observed transport rate of vapreotide across porcine epidermis and its clinical
pharmacokinetics, therapeutic concentrations should be achievable using a 15-cm2 patch.
KEY WORDS: electroosmosis; skin barrier; transdermal iontophoresis; vapreotide.
INTRODUCTION
Vapreotide is one of several potent long-acting ana-
logues of somatostatin synthesized for clinical use in the
treatment of acromegaly and endocrine tumors of the gas-
troenteropancreatic system. In addition, it has been success-
ful in the early treatment of esophageal variceal bleeding and
has been awarded orphan drug status in the United States
(1). These analogues require subcutaneous or intramuscular
administration. In an attempt to avoid the parenteral route,
more convenient Bpatient-friendly^ routes of drug delivery
have been investigated. The results have been mixed: orally
administered octreotide (another somatostatin analogue
commercialized as Sandostatin\) is hampered by a relatively
low bioavailability (2) and because of poor local tolerability,
nasal administration is also inconvenient (3). The transder-
mal route is an attractive alternative to deliver therapeutic
drugs (4). The physicochemical properties of peptides
(charged; high molecular weight) render them inappropriate
for passive transdermal delivery. In contrast, iontophoresis,
an electrically assisted drug delivery technology, offers a
controlled and noninvasive means of administration (5). The
two main transport mechanisms during iontophoresis are
electromigration (direct effect of the applied electric field on
the charged species) and electroosmosis (convective solvent
flow in the anode-to-cathode direction, as a consequence of
the skin’s net negative charge at physiological pH). Since
electrical mobility decreases with molecular weight, it is
hypothesized that electroosmosis is the major transport
mechanism for peptides (6). It is also known, however, that
peptides containing adjacent cationic and lipophilic residues
can inhibit electroosmosis, and their own transport, by
altering skin permselectivity (7Y12). The association of these
lipophilic cations with the membrane neutralizes, to varying
extents, the intrinsic negative charge of the skin causing a
significant reduction in the normal anode-to-cathode electro-
osmotic flow. Since the degree of inhibition depends on the
number of molecules in the skin, it is usually more
pronounced at higher applied current densities and at
increased peptide concentrations.
The iontophoretic delivery of octreotide has been suc-
cessfully achieved in rabbits in vivo (13). An investigation of
the effect of current density and drug concentration on
plasma levels of octreotide revealed a decrease in the amount
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of peptide delivered, with increasing concentration. This
might be attributed to an inhibition of electroosmosis, since
the -Phe3-D-Trp4-Lys5- sequence in octreotide corresponds to
the structural moiety thought to be a prerequisite for this
phenomenon (10).
The aim of the current study was to evaluate the fea-
sibility of delivering vapreotide by transdermal iontophoresis.
In view of the structural similarity of vapreotide to octreotide,
the iontophoretic delivery of vapreotide was expected to affect
electroosmotic solvent flow. Hence, in addition to quantifying
peptide transport, the magnitude of electroosmotic flow was
also determined under the different experimental conditions
employed. Experiments were also conducted in the presence
of a salt bridge; this allowed the use of lower electrolyte
concentrations in the donor compartment, decreasing the
number of competing charge carriers and, in theory, increasing
peptide delivery efficiency (5). The impact of current density
and salt bridge use on both peptide transport and electroos-
motic inhibition was measured. Different approaches to
modulate the interactions between the peptide and the skin
were investigated, including co-iontophoresis with cetrimide,
pre- and post-iontophoretic treatment of the skin with Ca2+
and propranolol substances capable of interacting with the
biomembrane and occupying potential Bpeptide^ binding
sites. Vapreotide transport across heat-separated epidermis
and dermatomed skin was compared.
MATERIALS AND METHODS
Chemicals
Vapreotide (MW = 1131.4), D-Phe-Cys-Tyr-D-Trp-Lys-
Val-Cys-Trp-NH2, in the form of its acetate salt, was a
generous gift from Debiopharm (Debiopharm Galenic Unit,
Gland, Switzerland). Acetaminophen was purchased from
Fluka (Sigma-Aldrich Chimie, Saint Quentin Fallavier,
France). Tris [Tris-(hydroxymethyl) aminomethane],
Trizma\ hydrochloride, agarose, DL-propranolol, and cetri-
mide were obtained from Sigma-Aldrich (Sigma-Aldrich
Chimie, Saint Quentin Fallavier, France) and bovine serum
albumin was purchased from Fluka BioChemika (Sigma-
Aldrich Chimie, Saint Quentin Fallavier, France). De-ionized
water (resistivity > 18 MOhm/cm2) was used to prepare all
solutions.
Analytical Procedures
Vapreotide extracted from skin samples was quantified
using a high-performance liquid chromatography system
equipped with a variable wavelength UV detector (Waters
Corporation, Milford, MA). The mobile phase, comprising
25% acetonitrile and 75% triethylaminephosphate buffer
solution (pH 2.3), was passed through a C18 PartiSphere
column (4.6 mm i.d., 12.5 cm long, 5 mm particle size)
(Whatman Inc., Florham Park, NJ) maintained at 40-C, at a
flow rate of 1 ml/min. The peptide was detected at 280 nm.
The RSD of the repeatability was less than 1% and the limit
of quantification was 115 ng/ml. Direct competitive enzyme
immunoassay (EIA), as a result of its superior sensitivity, was
used to quantify the presence of vapreotide in the receptor
compartment. This competitive binding assay is based on the
relative affinity of (1) the vapreotide (in the sample) and (2)
an enzymatic tracer prepared by covalent coupling of
vapreotide to an enzyme (acetylcholinesterase), to anti-
vapreotide antibodies. The quantification limit corresponded
to 100 pg/ml.
Acetaminophen was assayed by high-performance
liquid chromatography using a Hypersil BDS C8 column
(150 mm  4.6 mm, Supelco\, Sigma-Aldrich Chimie, Saint
Quentin Fallavier, France) maintained at 40-C. The mobile
phase (delivered at a flow rate of 1 ml/min) consisted of
92% water and 8% acetonitrile adjusted to pH 3.5 with
acetic acid. Acetaminophen was detected by its ultraviolet
(UV) absorbance at 243 nm. The RSD of the repeatability
was less than 1% and the quantification limit was 22 ng/ml.
Skin Preparation
Porcine ears, obtained from a local abbatoir (Socie´te´
d’Exploitation d’Abbatage, Annecy, France) within a few
hours postmortem, were cleaned under cold running water.
The whole skin was removed carefully from the outer region
of the ear and separated from the underlying cartilage with a
scalpel. The tissue was then either dermatomed (800 mm) or
heat-treated to separate the epidermis (14): pieces of fresh
full-thickness skin were immersed in water at 58-C for 2 min
after which the epidermis was carefully separated from the
dermis with a spatula. Pieces of epidermis and dermatomed
skin were wrapped individually in Parafilmi and maintained
at Y20-C until use and were stored for no longer than a
period of 2 months.
Iontophoresis Procedure
The skin was clamped in three-compartment vertical
diffusion cells (area: 0.73 cm2), the design of which has been
previously described (15). Unless otherwise stated, va-
preotide was dissolved in a 100 mM NaCl solution that was
adjusted to pH 5.5 with HCl to produce a 3 mM solution
of the peptide; 1 ml of this solution was placed in the donor
(anodal) compartment. In addition to vapreotide, the donor
compartment always contained 15 mM acetaminophen. The
cathodal compartment was filled with 1 ml of 25 mM Tris/
Trizma\ HCl-buffered (pH 7.4) normal saline. The receptor
compartment (õ6 ml) was filled with the same electrolyte
solution, containing in addition, when stated, 44 g/L of bo-
vine serum albumin (BSA; to mimic physiological conditions)
and was stirred magnetically throughout the permeation
experiments.
Constant current iontophoresis was used throughout the
study. The current, ranging from 0.05 to 0.5 mA/cm2, was
applied for 4Y24 h via Ag/AgCl electrodes connected to a
power supply (Kepco, Flushing, NY).
When specified, the anode was isolated from the donor
solution via a salt bridge (100 mM Tris/Trizma HCl in 3%
agarose) to minimize the competition between the peptide
and the electrolytes necessary for the anodal reaction. Under
these conditions, the anodal compartment contained a
solution of 25 mM Tris/Trizma\ HCl normal saline buffered
to pH 7.4 and the vapreotide in the donor compartment was
dissolved in 20 mM Tris/Trizma\ HCl (pH 7.4). Schematic
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representations of these two different experimental set-ups
are provided in Fig. 1.
Quantifying Electroosmotic Inhibition
Acetaminophen is a neutral hydrophilic compound, with
poor passive permeability (õ2 nmol/cm2 per hour); under the
influence of an electrical current, this uncharged but polar
molecule is driven through the skin predominantly by
electroosmosis. Hence, in these studies it was incorporated
into the donor formulation (15 mM) to report on convective
solvent flow.
For each experiment, an inhibition factor (IF) was cal-
culated using the following equation:
IF ¼ QA<8h;control
 
QA<8h;peptide
  ð1Þ
where QA-8h,control is the amount of acetaminophen trans-
ported into the receptor phase during 8 h of iontophoresis
when no peptide was present in the donor solution, and
QA-8h, peptide is the corresponding quantity when vapreotide
was iontophoresed.
Effect of Current Density
To evaluate the effect of current density on electroos-
motic inhibition by vapreotide, current densities of 0.15,
0.3, and 0.5 mA/cm2 were applied for 8 h across derma-
tomed skin. A solution of 3 mM vapreotide in 20 mM Tris/
Trizma\ HCl buffered to pH 7.4 was placed in the donor
compartment.
Additional experiments were also performed using heat-
separated epidermis to assess the effect of current density on
the amount of vapreotide transported. Again, a 3 mM
vapreotide donor solution was iontophoresed for 8 h.
Vapreotide Accumulation in the Skin
The uptake of vapreotide into dermatomed skin during
iontophoresis was also investigated. On terminating current
application, the skin sample was rinsed with water, dried on
absorbent paper, and then placed in 4 ml of a mixture
acetonitrile/water (25:75). After agitation for 14 h, the
solution was filtered (0.45 mm regenerated cellulose syringe
filter, Alltech, Deerfield, IL) and the amount of peptide
quantified.
Skin Metabolism Experiments
The influence of porcine ear skin on the stability of
vapreotide was evaluated by filling the receptor compartment
with a 5 mM vapreotide solution in 25 mM Tris/Trizma\
HCl-buffered (pH 7.4) normal saline. Both dermatomed and
epidermal skin samples were evaluated separately. The
anodal and cathodal compartments were filled with 1 ml of
25 mM Tris /Trizma\ HCl-buffered (pH 7.4) normal saline.
A current of 0.15 mA/cm2 was applied for 8 h and the
percentage of intact peptide was calculated as follows:
Intact peptide %ð Þ ¼ Final amount of peptide
Initial amount of peptide
 100% ð2Þ
Modifying Interactions Between Vapreotide and the Skin
Co-Iontophoresis
One milliliter of 4.4 mM vapreotide in 20 mM Tris/
Trizma\ HCl (pH 7.4) containing either 0.1% or 1% (2.7 or
27 mM) cetrimide was placed in the anodal compartment and
a current of 0.15 mA/cm2 was applied for either 8 or 24 h.
Pretreatment
Vapreotide iontophoresis was preceded by the ionto-
phoretic delivery of either propranolol or cetrimide:
A: A solution of 40 mM propranolol or 0.1% cetrimide
in 25 mM Tris /Trizma\ HCl (pH 7.4) normal saline was
placed in the anodal compartment and a current of 0.3 mA/
cm2 was applied for 8 h.
B: Subsequently, 1 ml of 4.4 mM vapreotide in 20 mM
Tris / Trizma\ HCl (pH 7.4) was placed in the donor
compartment and a current of 0.15 mA/cm2 was applied for
24 h using a salt bridge.
Post-Treatment
Solutions of CaCl2, NaCl, propranolol, and cetrimide
were tested with respect to their capacity to release vapreo-
tide bound to, and accumulated within, dermatomed skin.
Fig. 1. Schematic representations of the iontophoretic diffusion cell
assemblies used in this study.
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These experiments also comprised two parts:
A: 1 ml of vapreotide (3 mM) in 20 mM Tris/Trizma\
HCl (pH 7.4) was placed in the donor compartment and a
current of 0.15 mA/cm2 was applied for 24 h using a salt
bridge.
B: Solutions of either 100 mM CaCl2, 100 mM NaCl, 40
mM propranolol, or 0.1% cetrimide in 25 mM Tris/Trizma\
HCl (pH 7.4) normal saline were added to the anodal
compartment and a current of 0.3 mA/cm2 was applied for
8 h.
For each pre- and post-treatment experiment, the re-
ceptor compartment was replaced between phase A and
phase B.
Data Treatment
The results were derived from at least triplicate experi-
ments conducted with skin samples originating from different
pig ears. Outliers, determined using the Grubbs test, were
discarded. When two sets of data where compared, Student
t-tests were performed. The level of statistical significance
was fixed at p < 0.05.
RESULTS AND DISCUSSION
Skin Metabolism of Vapreotide
Cutaneous metabolism has been widely investigated
(16Y18) and several studies into transdermal peptide delivery
have reported the presence of proteolytic activity in the skin
(9,19Y21). With the concentration tested, only 39 T 18% of
the vapreotide in contact with the dermal face of dermatomed
skin samples was found to be intact after 8 h of iontophoresis.
Similarly, only 32 T 11% of the peptide remained intact after
exposure to the interior epidermal surface. The levels of
degradation observed following exposure to either derma-
tomed skin or isolated epidermis were not significantly
different.
Although the presence of proteolytic enzymes in the
skin is generally accepted, their exact location and distribu-
tion in the distinct tissue layers of the skin remains unknown.
Although the epidermis is claimed to be the major site of
drug degradation, activity has also been ascribed to the
dermis (17). Skin contact studies with vapreotide suggest that
both epidermal and dermal tissues possess some form of
proteolytic activity. Moreover, the results also demonstrate
that the enzymes located in the epidermis are resistant to the
heat separation treatment used to isolate the epidermal
membrane.
Nevertheless, it is difficult to extrapolate these in vitro
results to the eventual situation in vivo (particularly in
humans), notably owing to major interspecies differences in
the structure and function of such enzymes. In addition, the
residence time of the peptide in the enzymatic barrier is
likely to be significantly reduced in vivo as molecules
reaching the epidermalYdermal junction are taken up rapidly
by the skin’s microcirculation. Although enzymatic activity is
expected to be higher in viable tissues, it can be argued that
ex vivo skin preparation procedures might result in increased
release of intracellular enzymes. However, the skin tissue
used in these permeation experiments was frozen prior to
use, a process reported to reduce metabolic activity of skin
samples (22). Thus, in vitro/in vivo correlations for labile
peptides are complicated by the interplay of these opposing
factors.
Vapreotide Transport
Under the same iontophoretic conditions, significantly
more (õ10-fold) vapreotide was transported across the
epidermis (õ10 mg) than across dermatomed skin (õ1 mg)
when using the experimental set-up employing a salt-bridge
(Fig. 2). It is generally accepted that the remarkable barrier
function of the skin is primarily located in the outermost
layer of the epidermis, the stratum corneum, and that, in
vivo, substances are taken up by the capillary network
adjacent to the epidermalYdermal junction, after diffusing
on the order of 100 mm through the membrane. In separate
studies (data not shown), there was no difference between
the amount of vapreotide transported across tape-stripped
and intact dermatomed skin, suggesting that the stratum
corneum was not the rate-limiting barrier to transport at least
under in vitro conditions. The use of dermatomed skin (õ800
mm in thickness) in these in vitro experiments introduces an
additional mass of dermal tissue, which acts as a Bpseudo-
receptor^ compartment, notably for compounds such as
vapreotide, which display a high skin affinity. Therefore,
the presence of dermis provides an artifactual reservoir for
the drug that has already crossed the epidermis, and which, in
vivo, would be taken up by the capillaries just below the
epidermalYdermal junction. Thus, epidermis, which is a well-
established model for transdermal drug delivery, appears to
be more appropriate than dermatomed skin for transdermal
vapreotide transport studies. The fate of a peptide reservoir
in vivo, if indeed it exists, remains to be studied.
Vapreotide Accumulation in the Skin
Despite the inefficient transfer of vapreotide across
dermatomed skin, significant amounts of the peptide
(80Y300 mg) were recovered from the skin samples after
Fig. 2. Cumulative amount of vapreotide measured in the receptor
compartment after 8 h of iontophoresis at 0.15 mA/cm2 across
epidermis and dermatomed skin as a function of the experimental
set-up. (A: with salt bridge, B: without salt bridge, C: without salt
bridge; with BSA). There were statistically significant differences
between epidermis and dermatomed skin in each corresponding
experimental condition ( p < 0.05).
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iontophoresis (Table 1). These peptide accumulation data
further attest to the suspected strong association between
molecules possessing a positive charge, in close proximity to a
lipophilic surface, and the skin. In addition to these specific
interactions between the peptide and structures present in the
skin, the accumulation may also be the result of peptideY
peptide interactions, which result in vapreotide aggregation
and eventually in peptide deposition in the transport path-
ways.
Effect of Vapreotide Transport on Skin Permselectivity
Previous studies investigating iontophoretic transport
across hairless mouse, rabbit, porcine, and human skin have
confirmed the existence of skin permselectivity, a phenome-
non that gives rise to electroosmosis and contributes to the
iontophoretic transport of neutral and cationic species
(23Y25). Moreover, the ability of certain lipophilic, peptidic
and non-peptidic cations to inhibit the convective solvent
flow has also been established (10,11,26). The magnitude and
significance of this inhibition depend on the skin type and the
physicochemical properties of the molecule. The effect of
current density on the inhibition of electroosmosis by
vapreotide is illustrated in Fig. 3. The inhibitory capacity of
vapreotide is strongly dependent on the applied current
density, increasing the inhibition factor by almost 50-fold at
0.5 mA/cm2. As current density is increased, more charge has
to be transported across the skin; this is partly carried by the
peptide, which is driven into the membrane in greater
amounts, leading to a more extensive neutralization of the
skin’s negative charge and a more pronounced inhibition of
electroosmosis.
Effect of Reducing Competing Ions in the Formulation
Because Ag/AgCl electrodes need chloride ions for
anodal electrochemistry, the anodal compartment must
contain a supply of such ions derived from either the active
agent (e.g., hydrochloride salts) or from an external source
(e.g., NaCl), in which case the total number of cations in the
anodal formulation is greatly increased. These cations
compete with the positively charged drug as charge carriers.
The use of a salt bridge enables fewer competing cations
(õ20 mM) to be incorporated in the donor compartment,
increasing vapreotide transport efficacy, as indicated in Fig.
2. To confirm that the ionic strength and not the donor pH,
which also varied between the two experimental set-ups, was
responsible for the modified transport of vapreotide, the
effect of pH was also investigated. A control experiment
using the Bsalt bridge^ set-up was performed at pH 5.5 and
revealed that there was no significant difference in the
quantity of vapreotide transported (11.9 T 3.8 mg/cm2 at pH
5.5 vs. 10.7 T 4.5 mg/cm2 at pH 7.4).
Figure 4 indicates that the inhibition factor is increased
twofold in the presence of the salt bridge. As discussed
earlier, vapreotide transport increases with use of a salt
bridge; hence, more peptide reaches the skin membrane,
resulting in a more complete neutralization of skin charge
and, as a result, greater reduction in electroosmotic flow.
However, this increased inhibition is not sufficient to out-
weigh the increased transport resulting from the reduced ion
competition (Fig. 2). Finally, the degree of electroosmotic
inhibition was also independent of the skin preparation and
experimental conditions employed (Fig. 4).
In addition to increasing the proportion of charge
carried by the peptide, salt bridges allow the isolation of
the peptide from the electrode compartment and have the
Table I. Vapreotide Accumulation in the Skin After Iontophoretic
Current Application for 8Y24 h Using Formulations Containing
1.5Y4.4 mM Vapreotide
Experimental condition
Amount of vapreotide
in the skin (mg)
24 h iontophoresis at 0.15 mA/cm2,
4.4 mM donor concentration
210 T 10
8 h iontophoresis at 0.15 mA/cm2,
3 mM donor concentration
80 T 20
18 h iontophoresis at 0.5 mA/cm2,
1.5 mM donor concentration
300 T 60
Experiments were conducted using the experimental set-up shown in
Fig. 1B.
Fig. 3. Cumulative amounts of acetaminophen delivered across
porcine ear skin during 8 h of transdermal iontophoresis at 0.05,
0.15, and 0.5 mA/cm2 in the presence and absence of vapreotide. The
inhibition factor is calculated according to Eq. (1).
Fig. 4. The electroosmotic inhibition factor after 8 h of iontophoresis
at 0.15 mA/cm2 across epidermis and dermatomed skin as a function
of the experimental set-up. (A: with salt bridge, B: without salt
bridge, C: without salt bridge; with BSA). There were statistically
significant differences between the IFs observed with and without salt
bridges for both epidermal and dermatomed skin samples (p < 0.05).
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advantage of preventing interactions between the electrode
and the drug. Patch-based iontophoretic systems employing
the same principles have been developed in which the
electrode is separated from the drug reservoir by a size
exclusion membrane (27).
Modifying Interactions Between Vapreotide and the Skin
Given the substantial amounts of peptide measured in
the skin, the liberation and subsequent transport of even a
small fraction of this bound peptide would result in the
delivery of significant amounts of drug. A number of
different approaches, as shown in Fig. 5, were employed to
modulate the impact of peptideYskin interactions on vapreo-
tide transport.
The first approach involved co-iontophoresis of the cat-
ionic surfactant, cetrimide. The results in Fig. 6A show that
co-iontophoresis of 0.1% cetrimide led to a twofold reduction
in the amount of peptide recovered from the skin. As shown
in Fig. 6B, increasing the cetrimide concentration from 0.1%
to 1% produced a greater effect. Although it is tempting to
attribute this to an interaction of the cationic cetrimide with
putative binding sites, the observation that peptide transport
through the membrane was not increased suggests that the
surfactant itself acted as a competing charge carrier.
To exclude the risk of competition, subsequent studies
employed pre- and post-treatment of the skin wherein
cetrimide and other species known to bind to the membrane,
for example, Ca2+ and propranolol, were iontophoresed
either prior to or after vapreotide iontophoresis. It has been
proposed that the lower transport number of Ca2+ as compared
to Na+ is attributable to its superior interaction with neg-
atively charged binding sites in the skin (28). Likewise, the
iontophoresis of propranolol (40 mM) has been shown
to reduce the electroosmotic transport of mannitol across
porcine ear skin (26). Pre-iontophoretic treatment with either
cetrimide or propranolol was thus attempted to saturate the
putative binding sites, and hence prevent the interaction of
vapreotide with the skin. Vapreotide transport following
these pretreatments was not statistically different from the
control ( p < 0.05). Previous reports showed that cetrimide
pretreatment reduced iontophoretic delivery of propranolol
and this was attributed to a neutralisation of skin charge (29).
Based on the acetaminophen flux measured in our studies,
inclusion of cetrimide in the peptide formulation produced
an approximately twofold increase in electroosmotic inhi-
bition as compared to iontophoresis of vapreotide alone;
Fig. 5. Experimental strategies investigated to reduce the degree of vapreotide
fixation to the skin.
Fig. 6. Effect of co-iontophoresis of cetrimide on the amount of
vapreotide bound to the skin. (A) Co-iontophoresis of 0.1%
surfactant with 4.4 mM vapreotide for 24 h at 0.15 mA/cm2. (B)
Co-iontophoresis of 0.1% and 1% surfactant with 4.4 mM vapreotide
for 8 h at 0.15 mA/cm2.
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furthermore, it may also accumulate in the transport path-
ways impeding vapreotide passage. Post-iontophoretic treat-
ment methods were investigated with the aim of displacing
bound peptide from the skin. However, almost negligible
amounts of the peptide (<20 ng/cm2) were released after 8 h
of post-iontophoretic treatment with the different cationic
species tested.
Taken together, these results indicate that the strategies
employed to modify skinYvapreotide interactions in order to
improve peptide delivery were unsuccessful.
Can Therapeutic Amounts of Vapreotide be Delivered?
To compare our in vitro vapreotide transport studies
with the earlier in vivo investigation conducted by Lau et al.
into the transdermal iontophoresis of octreotide (13), the
final set of permeation experiments were conducted without
a salt bridge and with BSA in the receptor compartment. The
amounts of vapreotide reaching the receptor compartment
after 4, 6, and 8 h of iontophoretic current application (0.15
mA/cm2) are shown in Fig. 7. These cumulative quantities
were used to estimate the vapreotide flux at 7 h (1.7 mg/cm2
per hour). Since the experimental conditions chosen for the
in vitro study were similar to those used by Lau et al. for the
iontophoretic delivery of octreotide acetate in the rabbit, a
comparison of the transport of these two somatostatin
analogues is feasible. After 8 h of iontophoresis at 0.15 mA/
cm2, the plasma concentrations of octreotide were 0.85 and
1.7 ng/ml with donor concentrations of 2.5 and 5 mg/ml,
respectively (13). Based on our vapreotide data (donor
concentration of 3 mM ﬃ 3.9 mg/ml) and the relationship
equating flux to plasma concentration (steady-state flux 
area = clearance [plasma]), it is possible to estimate the
plasma concentration of vapreotide if it were delivered to the
rabbit under similar conditions (assuming the same clearance
of 2.3 L/h); the estimated value is 0.7 ng/ml, suggesting a
slightly lower transport for vapreotide than for octreotide.
Aside from the subtle differences in amino acid sequence,
this might be due in part to (1) the different skin models used
in the two studies (rabbit skin is recognized as being more
permeable than porcine skin) and (2) the aforementioned
differences in metabolic activities (both inter-species and
in vitro/in vivo).
Given a total vapreotide clearance of 16.7 L/h in humans
(personal communication), an input rate of õ25 mg/h must be
achieved in order to maintain a therapeutic level of 1.5 ng/ml.
In view of the experimental in vitro flux (1.7 mg/cm2 per
hour), it follows that a patch of õ15 cm2 could achieve the
desired delivery kinetics. Moreover, given the modest
experimental conditions used in this preliminary study, the
enhancement of vapreotide delivery by further fine-tuning
of the formulation and current profile is a realizable goal.
For example, the results obtained with a salt bridge system
clearly demonstrate that vapreotide transport can be en-
hanced by reducing the number of extraneous ions. Hence,
based on the data presented here, the transdermal iontopho-
retic delivery of therapeutic amounts of vapreotide certainly
appears to be feasible.
CONCLUSIONS
As with the luteinizing hormone releasing hormone
analogues, nafarelin and leuprolide, and other nonpeptidic
compounds that possess a structural motif characterized by
the close proximity of charge and lipophilicity (e.g., propran-
olol and quinine), vapreotide has been shown to interact with
the skin membrane. The degree of electroosmotic inhibition
increased with increasing current density. As a consequence
of this interaction, and perhaps the aggregation of the
peptide, large quantities of vapreotide were found in the
skin. The pretreatment strategies to saturate the skin binding
sites and the post-treatment methods to displace bound
vapreotide proved ineffective. It was also shown that sig-
nificantly greater amounts of peptide were transported across
heat-separated epidermis than across dermatomed skin.
Vapreotide was susceptible to a significant degree of me-
tabolism (õ60Y70%) when placed in contact with the in-
terior surface of heat-separated epidermis or dermatomed
skin. Given its susceptibility to enzymatic degradation, and
its capacity to shut down electroosmotic solvent flow, vap-
reotide may not appear as an ideal candidate for transdermal
iontophoresis. Nevertheless, analysis of the cumulative
amounts permeated across the epidermis and the human
pharmacokinetics suggests that iontophoretic delivery might
be an effective alternative to the conventional parenteral
administration of vapreotide.
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